Literature DB >> 18710986

Bone and soft-tissue lesions: what factors affect diagnostic yield of image-guided core-needle biopsy?

Jim S Wu1, Jeffrey D Goldsmith, Perry J Horwich, Sanjay K Shetty, Mary G Hochman.   

Abstract

PURPOSE: To assess lesion-related and technical factors that affect diagnostic yield in image-guided core-needle biopsy (CNB) of bone and soft-tissue lesions.
MATERIALS AND METHODS: Institutional review board approval and verbal informed consent were obtained for a HIPAA-compliant prospective study of 151 consecutive CNBs of bone (n = 88) and soft-tissue (n = 63) lesions. Each CNB specimen was reported separately in the final pathology report. Diagnostic yield (total number of biopsies that yield a diagnosis divided by total number of biopsies) was calculated for all lesions and subgroups on the basis of lesion composition (lytic, sclerotic, soft tissue), lesion size (< or = 2, > 2 to 5, or > 5 cm), biopsy needle gauge, image guidance modality, number of specimens obtained, and specimen length (< 5, 5-10, or > 10 mm). The minimum number of specimens required to obtain a diagnosis was determined on the basis of the specimen number at which the diagnostic yield reached a plateau. Chi(2) And Wilcoxon rank-sum tests were performed in bivariate analyses to evaluate associations between each factor and diagnostic yield. Significant factors were evaluated with multivariate logistic regression.
RESULTS: Diagnostic yield was 77% for all lesions. Yield was 87% for lytic bone lesions and 57% for sclerotic bone lesions (P = .002). Diagnostic yield increased with larger lesions (54% for lesions < or = 2 cm, 75% for lesions > 2 to 5 cm, and 86% for lesions > 5 cm [P = .006]). There was no difference in diagnostic yield for bone versus soft-tissue lesions or according to needle gauge or image guidance modality. Diagnostic yield was 77% for bone lesions and 76% for soft-tissue lesions (P = .88). Yield was 83%, 72%, 77%, and 83% for biopsies performed with 14-, 15-, 16-, and 18-gauge needles, respectively (P = .57). Yield was 77% with computed tomographic guidance and 78% with ultrasonographic guidance (P = .99). Diagnostic yield increased with number of specimens obtained and with longer specimen length; it reached a plateau at three specimens for bone lesions and four specimens for soft-tissue lesions.
CONCLUSION: Diagnostic yield is higher in lytic than in sclerotic bone lesions, in larger lesions, and for longer specimens. Obtaining a minimum of three specimens in bone lesions and four specimens in soft-tissue lesions optimizes diagnostic yield. RSNA, 2008

Entities:  

Mesh:

Year:  2008        PMID: 18710986     DOI: 10.1148/radiol.2483071742

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  51 in total

1.  Percutaneous image-guided needle biopsy of rib lesions: a retrospective study of diagnostic outcome in 51 cases.

Authors:  George Chanetsa Jakanani; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2012-06-12       Impact factor: 2.199

2.  Accuracy of core-needle biopsy after contrast-enhanced ultrasound in soft-tissue tumours.

Authors:  Armanda De Marchi; Elena Maria Brach del Prever; Alessandra Linari; Simona Pozza; Lucia Verga; Ugo Albertini; Marco Forni; Gian Carlo Gino; Alessandro Comandone; Adalberto Maria Brach del Prever; Raimondo Piana; Carlo Faletti
Journal:  Eur Radiol       Date:  2010-06-27       Impact factor: 5.315

3.  Incidence of delayed complications following percutaneous CT-guided biopsy of bone and soft tissue lesions of the spine and extremities: a 2-year prospective study and analysis of risk factors.

Authors:  Ambrose J Huang; Elkan F Halpern; Daniel I Rosenthal
Journal:  Skeletal Radiol       Date:  2012-05-22       Impact factor: 2.199

4.  Factors influencing the diagnostic yield and accuracy of image-guided percutaneous needle biopsy of pediatric tumors: single-center audit of a 26-year experience.

Authors:  Eléonore Blondiaux; Méryle Laurent; Etienne Audureau; Sabah Boudjemaa; Chiara Sileo; Marion Lenoir; Linda Dainese; Catherine Garel; Aurore Coulomb; Hubert Ducou le Pointe
Journal:  Pediatr Radiol       Date:  2015-11-20

5.  Image guided core needle biopsy of musculoskeletal lesions: are nondiagnostic results clinically useful?

Authors:  Manjiri M Didolkar; Megan E Anderson; Mary G Hochman; Julia G Rissmiller; Jeffrey D Goldsmith; Mark G Gebhardt; Jim S Wu
Journal:  Clin Orthop Relat Res       Date:  2013-07-17       Impact factor: 4.176

6.  Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.

Authors:  Charles E Spritzer; P Diana Afonso; Emily N Vinson; James D Turnbull; Karla K Morris; Adam Foye; John F Madden; Kingshuk Roy Choudhury; Phillip G Febbo; Daniel J George
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

Review 7.  Bone and Soft-Tissue Biopsies: What You Need to Know.

Authors:  Dimitrios K Filippiadis; George Charalampopoulos; Argyro Mazioti; Kalliopi Keramida; Alexis Kelekis
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

8.  Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.

Authors:  Stephanie A Harmon; Michael J Tuite; Robert Jeraj
Journal:  Phys Med Biol       Date:  2016-10-03       Impact factor: 3.609

9.  Percutaneous guided biopsy for diagnosing suspected primary malignant bone tumors in pediatric patients: a safe, accurate, and cost-saving procedure.

Authors:  Antony Ceraulo; Antoine Ouziel; Emilie Lavergne; Lionel Perrier; Anne-Valérie Decouvelaere; Franck Chotel; Philippe Thiesse; Perrine Marec-Berard
Journal:  Pediatr Radiol       Date:  2016-12-10

10.  Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

Authors:  R R McKay; K A Zukotynski; L Werner; O Voznesensky; J S Wu; S E Smith; Z Jiang; K Melnick; X Yuan; P W Kantoff; B Montgomery; S P Balk; M-E Taplin
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-08-05       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.